Table 2.
Main conclusions of the studies assessing the secondary outcomes.
| First Author, Year of Publication | Main Conclusion |
|---|---|
| Healing Time | |
| Alamdari, 2021 [27] | Shorter healing time in the PRP group than in the control group |
| Driver, 2006 [34] | Shorter healing time in the PRP group than in the control group |
| Elbarbary, 2020 [35] | Shorter healing time in the PRP group than in the control group * |
| Elgarhy, 2020 [36] | Shorter healing time in the topical and injected PRP groups than in the control group * |
| Elsaid, 2020 [37] | Shorter healing time in the PRP group than in the control group * |
| Game, 2018 [38] | Shorter healing time in the PRP group than in the control group * |
| Helmy, 2021 [43] | Shorter healing time in the PRP group than in the control group * |
| Kulkarni, 2019 [47] | Shorter healing time in the PRP group than in the control group * |
| Li, 2015 [48] | Shorter healing time in the PRP group than in the control group * |
| Obolenskiy, 2014 [53] | Shorter healing time in the PRP group than in the control group |
| Obolenskiy, 2017 [52] | Shorter healing time in the PRP group than in the control group * |
| Saad Setta, 2011 [59] | Shorter healing time in the PRP group than in the control group * |
| Singh, 2018 [63] | Shorter healing time in the PRP group than in the control group * |
| Yang, 2017 [69] | Shorter healing time in the PRP group than in the control group * |
| Infection Rates | |
| Abd El-Mabood, 2018 [25] | More infection in the control group than in the PRP group * |
| Ahmed, 2017 [26] | More infection in the control group than in the PRP group * |
| Amato, 2020 [28] | More infection in the control group than in the PRP group * |
| Anitua, 2008 [29] | No statistically significant difference between the PRP and the control groups |
| Burgos-Alonso, 2018 [30] | No statistically significant difference between the PRP and the control groups |
| de Oliveira, 2017 [33] | No statistically significant difference between the PRP and the control groups |
| Game, 2018 [38] | No statistically significant difference between the PRP and the control groups |
| Khorvash, 2017 [46] | No statistically significant difference between the PRP and the control groups |
| Li, 2015 [48] | No statistically significant difference between the PRP and the control groups |
| Pires, 2021 [54] | No statistically significant differences in antimicrobial resistance between P. aeruginosa and S. aureus in the PRP and control groups. PRP decreased bacteriological growth or the microbial load and resistance profile in the case of P. aeruginosa |
| Rainys, 2019 [57] | No statistically significant difference between the PRP and the control groups |
| Ramos-Torrecilla, 2015 [58] | No signs of infection were recorded during the study |
| Senet, 2003 [72] | No statistically significant difference between the PRP and the control groups |
| Yang, 2017 [69] | More infection in the control group than in the PRP group * |
| Pain | |
| Abd El-Mabood, 2018 [25] | Pain occurred more frequently in the control group * |
| Amato, 2020 [28] | Pain occurred more frequently in the control group * |
| Burgos-Alonso, 2018 [30] | No statistically significant difference in pain reduction between the PRP and the control groups |
| Cardenosa, 2017 [31] | Pain reduction was higher in the PRP group * |
| Game, 2018 [38] | No statistically significant difference in pain reduction between the PRP and the control groups |
| Glukhov, 2017 [39] | All patients subjectively experienced pain reduction in both groups |
| Helmy, 2021 [43] | All patients subjectively experienced pain reduction in the PRP group |
| Khorvash, 2017 [46] | pain reduction was higher in the PRP group * |
| Moneib, 2018 [51] | All patients subjectively experienced pain reduction in both groups |
| Saha, 2020 [60] | Administration-related pain was reported by 10 participants in the PRP group |
| Yang, 2017 [69] | pain reduction was higher in the PRP group * |
| Amputation Rates | |
| Alamdari, 2021 [27] | No statistically significant difference between the PRP and the control groups |
| Game, 2018 [38] | No statistically significant difference between the PRP and the control group |
| Gude, 2019 [42] | Two amputations in the control group and no amputation in the PRP group |
| Karimi, 2016 [45] | No statistically significant difference between the PRP and the control groups |
| Li, 2015 [48] | Four amputations in the control group one amputation in the PRP group |
| Pu, 2019 [55] | No statistically significant difference between the PRP and the control groups |
| Singh, 2018 [63] | Two amputations in the control group, and no amputation in the PRP group |
| Adverse Events | |
| Burgos-Alonso, 2018 [30] | No statistically significant difference between the PRP and the control groups |
| Cardenosa, 2017 [31] | No adverse events recorded |
| Chandanwale, 2020 [32] | No adverse event in the PRP group |
| Driver, 2006 [34] | No administration related serious adverse event was recorded in either group; one case of Contact dermatitis in the PRP group and one case of maceration in the control group |
| Game, 2018 [38] | No statistically significant difference between the PRP and the control groups |
| Helmy, 2021 [43] | No adverse events recorded |
| Kulkarni, 2019 [47] | No adverse event in the PRP group |
| Li, 2015 [48] | No adverse events were recorded in the PRP group |
| Moneib, 2018 [51] | No adverse events recorded |
| Rainys, 2019 [57] | No statistically significant difference between the PRP and the control groups, and no serious adverse event was recorded |
| Semenic, 2018 [61] | No adverse events recorded |
| Senet, 2003 [72] | No statistically significant difference between the PRP and the control groups |
| Singh, 2018 [63] | No adverse events recorded |
| Yang, 2017 [69] | No statistically significant difference between the PRP and the control groups |
PRP-platelet-rich plasma; * indicates significant difference (p < 0.05).